Stephen D. Collins
Direttore/Membro del Consiglio presso Xalud Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Daniel J. Abrams | M | - |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | - |
Stephen Farr | M | 65 |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | 6 anni |
Mike Huston | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Mahendra Shah | M | 79 |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | - |
Orrin Devinsky | M | 67 |
Engage Therapeutics, Inc.
Engage Therapeutics, Inc. BiotechnologyHealth Technology Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ. | - |
Daniel Lammertse | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Gerald Gebhart | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Ronald Dubner | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Charles Cleeland | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Brendan O’Leary | M | - |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | 3 anni |
Keyvan Mirsaeedi-Farahani | M | - |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | - |
Matthew Hammond | M | 35 |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | - |
Timothy Scannell | M | 60 |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | 2 anni |
Sean Stalfort | M | 53 |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Jayson M. Rieger | M | 48 |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Paul Manning | M | 68 |
Xalud Therapeutics, Inc.
Xalud Therapeutics, Inc. BiotechnologyHealth Technology Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA. | - |
Gerry Brunk | M | 55 |
Engage Therapeutics, Inc.
Engage Therapeutics, Inc. BiotechnologyHealth Technology Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ. | - |
Warren Lammert | M | - |
Engage Therapeutics, Inc.
Engage Therapeutics, Inc. BiotechnologyHealth Technology Engage Therapeutics, Inc. engages in the development of rescue therapy for uncontrolled epileptic seizures. The company was founded by Gregory T. Mayes III and Jouko Isojarvi in 2017 and is headquartered in Summit, NJ. | - |
Julie Foster | F | - |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Samuel Reich | M | 49 | 1 anni | |
Jeffrey Spragens | M | 82 | - | |
John Foster | M | - |
Cerebral Therapeutics, Inc.
Cerebral Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Cerebral Therapeutics, Inc. develops neurological therapeutics for uncontrolled neurological diseases. It is a clinical-stage company dedicated to improving the lives of patients living with uncontrolled neurological diseases, with an initial focus on refractory epilepsy. The firm offers long-term implanted drug-device combination therapies that bypass the blood-brain barrier to deliver optimal doses of specially formulated neurological therapeutics directly into the target region of the brain. The company was founded by Daniel J. Abrams and James P. Kelleher and is headquartered in Aurora, CO. | 4 anni |
James Martin | M | 57 | 1 anni | |
Ilan Katz | M | 52 | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 24 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Stephen D. Collins
- Contatti personali